ArticleCurrent microbiology2026
Identification of 4-Amino-7-chloroquinoline Derivative with In Vitro Activity Against Chikungunya Virus.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arboviruses such as chikungunya virus (CHIKV), Zika virus (ZIKV), and Mayaro virus (MAYV) represent significant global health challenges due to the lack of effective antiviral therapies. Quinoline-based compounds have emerged as promising scaffolds for antiviral drug development. In this study, five 4-amino-7-chloroquinoline derivatives were synthesized and evaluated for their in vitro antiviral activity against CHIKV, ZIKV, and MAYV in Vero cells. Cytotoxicity and antiviral effects were assessed using a tetrazolium-based assay, followed by complementary analyses including cytopathic effect inhibition, virucidal assay, and viral load quantification by RT-qPCR. Among the tested compounds, derivative 6 demonstrated the most pronounced anti-CHIKV activity, with a low micromolar effective concentration and moderate selectivity index. This compound significantly reduced viral replication, preserved cell monolayer integrity, and decreased viral titers, achieving substantial viral load reduction confirmed by RT-qPCR. No virucidal activity was observed. In contrast, compound 6 inhibited the virus-induced cytopathic effect when administered after viral adsorption, suggesting that its antiviral activity is unlikely to result from interference with viral attachment or adsorption but rather from inhibition of a post-adsorption stage of the viral replication cycle. Overall, these findings highlight 4-amino-7-chloroquinoline derivatives as a promising class of antiviral agents and identify compound 6 as a potential lead candidate for further development against CHIKV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.